Clinical trial
Open-Label Extension Of Intravenous Mepolizumab In Patients With…
NCT00097370 · GlaxoSmithKline, Industry · Terminated
Key facts
| NCT number | NCT00097370 |
|---|---|
| Title | Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome |
| Official title | An Open Label Extension Study to Evaluate Safety and Efficacy of Mepolizumab in Patients With Hypereosinophilic Syndromes |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypereosinophilic Syndrome |
| Intervention type | Drug |
| Interventions | mepolizumab |
| Enrollment | 78 |
| Start date | Sep 30, 2004 |
| Primary completion | Sep 29, 2010 |
| Completion | Sep 29, 2010 |
| First posted | Nov 23, 2004 |
| Last update posted | Jul 7, 2017 |
| Countries | Australia, Belgium, Canada, France, Germany, Italy, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: